On This Page
Taxotere (docetaxel) is an injectable chemotherapy drug approved in the treatment of breast cancer as well as other forms of cancer, including prostate, stomach, head and neck cancers, and non-small cell lung cancer. First approved by the FDA in 1996, Taxotere has recently spawned a number of lawsuits claiming that Taxotere’s manufacturer Sanofi-Aventis knew, or should have known, that the drug may cause permanent hair loss, and that Sanofi failed to adequately warn of those risks. Plaintiffs allege that Sanofi was aware Taxotere was more likely to cause permanent hair loss compared to equally-effective alternative cancer treatments, and concealed this information from patients and doctors.
In December 2015, the FDA required Sanofi to change the drug’s label to include warnings of the risk of permanent hair loss. Since then, thousands of lawsuits against Sanofi have been filed, now totaling 8,500 pending suits. The first trial in the Taxotere multi-district litigation took place in September 2019 in the U.S. District Court for the Eastern District of Louisiana before The Honorable Jane Triche Milazzo.
Taxotere’s Adverse Side-Effects
While many chemotherapy drugs can cause temporary hair loss, or alopecia, Taxotere may cause permanent alopecia. Mention of permanent alopecia as a possible side-effect of Taxotere was added to the drug’s U.S. prescribing information in December 2015.
Who Is Eligible to File a Lawsuit?
You may be legally entitled to compensation if you were prescribed Taxotere as chemotherapy treatment and experienced permanent hair loss.
Experienced attorneys at Grant & Eisenhofer are investigating the risks of Taxotere and are monitoring all developments. If you or a loved one were prescribed Taxotere for the treatment of breast cancer and suffered permanent hair loss, please contact us by submitting the form or by calling us at (888) 984-7988 for a confidential evaluation of your potential claim.